Briquilimab (JSP191)
Conditioning for allogeneic hematopoietic cell transplant in Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)
Key Facts
About Jasper Therapeutics
Jasper Therapeutics is pioneering a new approach to conditioning, a critical step before stem cell transplant or gene therapy. Its lead program, briquilimab, targets the c-Kit receptor on HSCs to create space for donor or gene-corrected cells, aiming to replace toxic chemotherapy and radiation. The company is advancing briquilimab in multiple clinical settings, including for patients with severe combined immunodeficiency (SCID) and as part of gene therapy regimens. Jasper's mission is to expand access to and improve the safety of curative treatments.
View full company profileAbout Jasper Therapeutics
Jasper Therapeutics is pioneering a new approach to conditioning, a critical step before stem cell transplant or gene therapy. Its lead program, briquilimab, targets the c-Kit receptor on HSCs to create space for donor or gene-corrected cells, aiming to replace toxic chemotherapy and radiation. The company is advancing briquilimab in multiple clinical settings, including for patients with severe combined immunodeficiency (SCID) and as part of gene therapy regimens. Jasper's mission is to expand access to and improve the safety of curative treatments.
View full company profileAbout Jasper Therapeutics
Jasper Therapeutics is pioneering a new approach to conditioning, a critical step before stem cell transplant or gene therapy. Its lead program, briquilimab, targets the c-Kit receptor on HSCs to create space for donor or gene-corrected cells, aiming to replace toxic chemotherapy and radiation. The company is advancing briquilimab in multiple clinical settings, including for patients with severe combined immunodeficiency (SCID) and as part of gene therapy regimens. Jasper's mission is to expand access to and improve the safety of curative treatments.
View full company profileAbout Jasper Therapeutics
Jasper Therapeutics is pioneering a new approach to conditioning, a critical step before stem cell transplant or gene therapy. Its lead program, briquilimab, targets the c-Kit receptor on HSCs to create space for donor or gene-corrected cells, aiming to replace toxic chemotherapy and radiation. The company is advancing briquilimab in multiple clinical settings, including for patients with severe combined immunodeficiency (SCID) and as part of gene therapy regimens. Jasper's mission is to expand access to and improve the safety of curative treatments.
View full company profileAbout Jasper Therapeutics
Jasper Therapeutics is pioneering a new approach to conditioning, a critical step before stem cell transplant or gene therapy. Its lead program, briquilimab, targets the c-Kit receptor on HSCs to create space for donor or gene-corrected cells, aiming to replace toxic chemotherapy and radiation. The company is advancing briquilimab in multiple clinical settings, including for patients with severe combined immunodeficiency (SCID) and as part of gene therapy regimens. Jasper's mission is to expand access to and improve the safety of curative treatments.
View full company profile